首页> 外文期刊>Frontiers in Medicine >Case Report: Composite Angioimmunoblastic T-Cell Lymphoma and Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder as Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders
【24h】

Case Report: Composite Angioimmunoblastic T-Cell Lymphoma and Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder as Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders

机译:案例报告:复合血管免疫细胞T细胞淋巴瘤和Epstein-Barr病毒阳性B细胞淋巴抑制性疾病,作为其他性能免疫缺陷相关的淋巴抑制性疾病

获取原文
           

摘要

Immunosuppressants are widely used to treat patients with rheumatoid arthritis (RA), and their adverse effects have been known to cause other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs). We report a patient with RA who had been treated with methotrexate (MTX) and tacrolimus (TAC) and who developed whole body lymphadenopathy. We simultaneously confirmed angioimmunoblastic T-cell lymphoma (AITL) through a right cervical lymph node biopsy and Epstein-Barr virus-positive B-cell lymphoproliferative disorder (EBV-positive B-LPD) through a bone marrow examination. After cessation of immunosuppressant therapy, both lymphomas completely disappeared. Patients with AITL are occasionally reported to develop B-cell lymphoma through reactivation of the EBV, which leads to clonal expansion in the microenvironment. Immunohistochemistry results revealed that both lymphoma components were positive for EBV-encoded RNA. Moreover, in this patient, the plasma EBV DNA level was found to be high; therefore, EBV infection was a probable etiology. Synchronous coexistence of AITL and B-LPD as an OIIA-LPD has rarely been reported. This case report is the first to discuss the disappearance of both lymphomas on withdrawal of immunosuppressants only. AITL occasionally accompany B-LPD; however, this composite lymphoma comprised AITL and B-LPD, and OIIA-LPDs should not be overlooked.
机译:免疫抑制剂广泛用于治疗类风湿性关节炎(RA)的患者,已知其不良反应使其他性能免疫缺陷相关的淋巴抑制性疾病(OIIA-LPD)。我们向患有用甲氨蝶呤(MTX)和Tacrolimus(TAC)治疗的RA患者,以及开发全身淋巴结病的患者。我们通过骨髓检查同时通过右侧颈淋巴结活检和Epstein-Barr病毒阳性B细胞(EBV阳性B-LPD)来同时确认血管免疫细胞淋巴瘤(Ait1)。停止免疫抑制疗法治疗后,淋巴瘤都完全消失。偶尔据报道患有AIT1的患者通过EBV的再激活来发展B细胞淋巴瘤,这导致微环境中的克隆扩增。免疫组织化学结果表明,淋巴瘤成分均为EBV编码RNA阳性。此外,在该患者中,发现血浆EBV DNA水平高;因此,EBV感染是可能的病因。 AIT1和B-LPD作为OIIA-LPD的同步共存很少。本案例报告是第一个讨论淋巴瘤的消失仅在免疫抑制剂的撤离时。 Aitl偶尔伴随着B-LPD;然而,这种复合淋巴瘤包含AIT1和B-LPD,不应忽视OIIA-LPD。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号